Evidence map›Paper›PMID 33283037›Full record

ArticleAlzheimer's & dementia (New York, N. Y.)2020

Differentiating among stages of cognitive impairment in aging: Version 3 of the Uniform Data Set (UDS) neuropsychological test battery and MoCA index scores.

Hiroko H Dodge, Felicia C Goldstein, Nicole I Wakim, Tamar Gefen, Merilee Teylan, Kwun C G Chan, Walter A Kukull, Lisa L Barnes, Bruno Giordani, Timothy M Hughes and 13 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Alzheimer's & dementia (New York, N. Y.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Measurement equivalence of the UDS version 2.0 and 3.0 neuropsychological batteries.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  8. Observational
  9. Study partner characteristics moderate the prediction of cognitive decline in aging.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Aging gene signature of memory CD8Immunity & ageing : I & A · 2023
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 15 institutions in 1 country.

Hiroko H DodgeLayton Aging and Alzheimer's Disease Center Oregon Health & Science University Portland Oregon USA.
Felicia C GoldsteinGoizueta Alzheimer's Disease Research Center Emory University School of Medicine Atlanta Georgia USA.
Nicole I WakimDepartment of Biostatistics University of Michigan Ann Arbor Michigan USA.
Tamar GefenThe Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Department of Psychiatry and Behavioral Sciences, Feinberg School of Medicine, Northwestern University Chicago Illinois USA.
Merilee TeylanNational Alzheimer's Coordinating Center University of Washington Seattle Washington USA.
Kwun C G ChanNational Alzheimer's Coordinating Center University of Washington Seattle Washington USA.
Walter A KukullNational Alzheimer's Coordinating Center University of Washington Seattle Washington USA.
Lisa L BarnesRush Alzheimer's Disease Center Rush University Medical Center Chicago Illinois USA.
Bruno GiordaniMichigan Alzheimer's Disease Center University of Michigan Ann Arbor Michigan USA.
Timothy M HughesThe Wake Forest Alzheimer's Disease Research Center, Wake Forest School of Medicine Winston-Salem North Carolina USA.
Joel H KramerMemory and Aging Center University of California San Francisco San Francisco California USA.
David A LoewensteinCenter for Cognitive Neuroscience and Aging University of Miami Miller School of Medicine Miami Florida USA.
Daniel C MarsonAlzheimer's Disease Center University of Alabama at Birmingham Birmingham Alabama USA.
Dan M MungasThe UC Davis Alzheimer's Disease Research Center University of California, Davis Sacramento California USA.
Nora MattekLayton Aging and Alzheimer's Disease Center Oregon Health & Science University Portland Oregon USA.
Bonnie C SachsThe Wake Forest Alzheimer's Disease Research Center, Wake Forest School of Medicine Winston-Salem North Carolina USA.
David P SalmonThe Shiley-Marcos Alzheimer's Disease Research Center University of California, San Diego La Jolla California USA.
Monica Willis-ParkerGoizueta Alzheimer's Disease Research Center Emory University School of Medicine Atlanta Georgia USA.
Kathleen A Welsh-BohmerAlzheimer's Disease Research Center Duke University Durham North Carolina USA.
Katherine V WildLayton Aging and Alzheimer's Disease Center Oregon Health & Science University Portland Oregon USA.
John C MorrisKnight Alzheimer Disease Research Center Washington University School of Medicine St. Louis Missouri USA.
Sandra WeintraubThe Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Department of Psychiatry and Behavioral Sciences, Feinberg School of Medicine, Northwestern University Chicago Illinois USA.
National Alzheimer's Coordinating Center (NACC)
Oregon Health & Science University · USUniversity of Washington · USEmory University · USNorthwestern University · USWake Forest University · USAlzheimer’s Disease Neuroimaging Initiative · USDuke University · USMichigan United · USRush University Medical Center · USUniversity Memory and Aging Center · USUniversity of Alabama at Birmingham · USUniversity of California, Davis · USUniversity of Miami · USUniversity of Michigan–Ann Arbor · USWashington University in St. Louis · US

Funding

NATIONAL ALZHEIMERS COORDINATING CENTER (NACC)U01AG016976 · NIA · UNIVERSITY OF WASHINGTON · PI KUKULL, WALTER ANTHONY · 1999 to 2020
$72.8M
THERAPEUTIC EFFECTS OF INTRA-NASAL INSULIN DETEMIRP50AG005136 · NIA · UNIVERSITY OF WASHINGTON · PI JAYADEY, SUMAN · 1985 to 2019
$57.2M
VIRUS-INDUCED BRAIN PATHOLOGYP50AG005131 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BREWER, JAMES B · 1985 to 2018
$55.4M
WASHINGTON UNIVERSITY ALZHEIMERS DISEASE RESEARCH CENTERP50AG005681 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 1985 to 2019
$52.1M
SUPPLEMENT TO RUSH ALZHEIMERS DISEASE CENTER COREP30AG010161 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1991 to 2020
$49.1M
Satellite Diagnostic and Treatment Clinic CoreP50AG008702 · NIA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI DE JAGER, PHILIP L · 1989 to 2019
$46.3M
National Alzheimer's Coordinating CenterU24AG072122 · NIA · UNIVERSITY OF WASHINGTON · PI STEPHENS, KARI A · 2021 to 2025
$45.8M
TREATMENT OF DEPRESSION IN ALZHEIMER'S DISEASEP50AG005133 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BECKER, JAMES T. · 1985 to 2019
$43.0M
THE ROLE OF ADVANCED CAA IN ALZHEIMER'S DEMENTIAP50AG005134 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI HYMAN, BRADLEY T. · 1985 to 2018
$42.1M
VASCULAR RISK AND COGNITIVE STATUS IN A LATINO POPULATIONP50AG005142 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ARANDA, MARIA P. · 1985 to 2019
$41.0M
VESICULAR LOCALIZATION AND FUNCTION OF PRESENILIN 1 FRAGMENTP50AG005138 · NIA · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI SCHIMMING, CORBETT · 1985 to 2019
$37.9M
'T V ASSESSMENT - MEMORY DISORDERED PATIENTS'P50AG005146 · NIA · JOHNS HOPKINS UNIVERSITY · PI HUGANIR, RICHARD L · 1985 to 2019
$37.6M
NIA NIH HHS P30 AG008017NIA NIH HHS P30 AG008051NIA NIH HHS P30 AG010124NIA NIH HHS P30 AG010129NIA NIH HHS P30 AG010133NIA NIH HHS P30 AG010161NIA NIH HHS P30 AG012300NIA NIH HHS P30 AG013846NIA NIH HHS P30 AG013854NIA NIH HHS P30 AG019610NIA NIH HHS P30 AG028383NIA NIH HHS P30 AG035982NIA NIH HHS P30 AG049638NIA NIH HHS P30 AG053760NIA NIH HHS P30 AG062429NIA NIH HHS P30 AG066511NIA NIH HHS P30 AG066518NIA NIH HHS P30 AG072976NIA NIH HHS P50 AG005131NIA NIH HHS P50 AG005133NIA NIH HHS P50 AG005134NIA NIH HHS P50 AG005136NIA NIH HHS P50 AG005138NIA NIH HHS P50 AG005142NIA NIH HHS P50 AG005146NIA NIH HHS P50 AG005681NIA NIH HHS P50 AG008702NIA NIH HHS P50 AG016573NIA NIH HHS P50 AG016574NIA NIH HHS P50 AG023501NIA NIH HHS P50 AG025688NIA NIH HHS P50 AG033514NIA NIH HHS P50 AG047266NIA NIH HHS P50 AG047270NIA NIH HHS P50 AG047366NIA NIH HHS R01 AG062566NIA NIH HHS U01 AG016976NIA NIH HHS U24 AG072122
6 · The paper itself

Abstract

introductionFederally funded Alzheimer's Disease Centers in the United States have been using a standardized neuropsychological test battery as part of the National Alzheimer's Coordinating Center Uniform Data Set (UDS) since 2005. Version 3 (V3) of the UDS replaced the previous version (V2) in 2015. We compared V2 and V3 neuropsychological tests with respect to their ability to distinguish among the Clinical Dementia Rating (CDR) global scores of 0, 0.5, and 1.

methodsFirst, we matched participants receiving V2 tests (V2 cohort) and V3 tests (V3 cohort) in their cognitive functions using tests common to both versions. Then, we compared receiver-operating characteristic (ROC) area under the curve in differentiating CDRs for the remaining tests.

resultsSome V3 tests performed better than V2 tests in differentiating between CDR 0.5 and 0, but the improvement was limited to Caucasian participants. DISCUSSION: Further efforts to improve the ability for early identification of cognitive decline among diverse racial groups are required.

Indexed as

differentiating CDRNational Alzheimer's Coordinating Center Uniform Data Set (NACC UDS)optimal cut‐pointracial differencesreceiver‐operating characteristic area under the curve (ROC‐AUC)validity

Identifiers

PMID33283037
PMCPMC7683960
OpenAlexW3108183223

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.